Medical Product companies Stryker CorporationSYK and Surmodics, Inc.SRDX are solid contenders in the U.S. MedTech space. Rapid innovation, major advances and aging population in the United States have sustained the popularity of healthcare stocks. Despite U.S.-China trade war-related uncertainties, 2019 is expected to witness new technologies, courtesy of the 2.3% Medical Device tax abatement along with focus on Artificial Intelligence and cybersecurity.
Considering this backdrop, it is difficult to choose between the above-mentioned companies as they have similar business models. The scales apparently look balanced as Stryker and Surmodics carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
However, we made a detailed analysis of the companies' fundamentals to determine which has a slight edge over the other.
Michigan-based Stryker is an orthopedic device giant and Minnesota-based Surmodics is a leading provider of medical device and In Vitro Diagnostics (IVD) technologies to the healthcare industry.
Price Performance & Style Score
In the past year, Stryker's shares have declined 3.1% compared with Surmodics' 67.4% surge. The Medical Products industry has declined 12.1% in the same time frame. Meanwhile, the S&P 500 index fell 12.4%.
Reflective of these favorable price movements, Stryker has a Momentum Score of A and the same for Surmodics is B. This reflects possibilities of outperformance at the moment. Our research shows that stocks with a Momentum Score of A or B, combined with a Zacks Rank #1 or 2, are better picks than most.
Which Way are Estimates Treading?
The Zacks Consensus Estimate for Stryker's fourth-quarter earnings per share (EPS) is pegged at $2.16, reflecting an improvement of 10.2% year over year. Surmodics' fiscal first-quarter loss per share is pegged at a penny, showing year-over-year decline of 110%.
Stryker Corporation Price and Consensus
The Zacks Consensus Estimate for Stryker's current-quarter revenues is pegged at $3.73 billion, suggesting growth of 7.5% from the previous year. The same for Surmodics is pegged at $18.90 million, reflecting a rise of 11.1% year over year.
Surmodics, Inc. Price and Consensus
What's Favoring the Stocks?
In the past four years, Stryker's revenues have witnessed a CAGR of 8.8% and reached $12 billion.
Meanwhile, Surmodics' revenues have witnessed a CAGR of 9.3% and reached $81 million in the past four years.
Veeva Systems' long-term earnings growth rate is projected at 19.5%. The stock flaunts a Zacks Rank #1.
Integer Holdings projects earnings growth rate of 31.2% for the fourth quarter. It currently carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.